Multiple Technology Appraisals in Scotland

Below are the NICE MTA alerts issued by Healthcare Improvement Scotland and our predessesor NHS Quality Improvement Scotland.

If Healthcare Improvement Scotland advise MTA guidance is applicable in Scotland, NHSScotland should take account of this and ensure that recommended medicines and treatment are made available to meet clinical need.

NICE MTA Guidance no 279 - Percutaneous vertebroplasty and percutaneous balloon kyphoplasty
NICE MTA guidance no 278 - Omalizumab for treating severe persistent allergic asthma
NICE MTA Guidance No 276 – Colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis
NICE MTA Guidance 265 - Bone metastases from solid tumours - denosumab
NICE MTA Guidance No 257 – Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-
NICE MTA Guidance No 251 - Dasatinib, nilotinib and standard-dose imatinib for treatment of chronic myeloid leukaemia
NICE MTA Guidance No 242 - Cetuximab, bevacizumab and panitumumab for the treatment of colorectal cancer
NICE MTA Guidance 241 - Dastinib, high-dose imatinib and nilotinib for the treatment of imatinib-restistant CML
NICE MTA Guidance No 246 – Pharmalgen for the treatment of bee and wasp venom allergy
Appraisal Guidance No 155 – Ranibizumab and Pegaptanib for Age-related Macular Degeneration
NICE MTA Guidance 243 - Rituximab for the first-line treatment of stage III–IV follicular lymphoma
Appraisal Guidance No 223 - Peripheral arterial disease
Appraisal Guidance No 228 – Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Appraisal 209 Imatinib for the treatment of unresectable and metastatic gastrointestinal stromal tumours
No 200 – Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Appraisal Guidance No 169– Sunitinib for the first line treatment of advanced and or metastatic renal cell carcinoma
Appraisal 210 'Clopidogrel and modified-release dipyridamole
Appraisal Guidance No 199 – Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Appraisal Guidance No 187 – Infliximab (review) and adalimumab for the treatment of Crohn’s disease
Appraisal Guidance No 195 – Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid
Appraisal Guidance No 184 – Topotecan for the treatment of relapsed small-cell lung cancer
Appraisal Guidance No 188 – Human growth hormone (somatropin) for the treatment of growth failure in children
Appraisal 217 'Donepezil, galantamine, rivastigmine and memantine'
Appraisal Guidance No 168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza
Appraisal Guidance No 178 - Renal Cell Carcinoma
Appraisal Guidance No 167 – Endovascular stent-grafts for the treatment of abdominal aortic aneurysms.
Guidance No 166 - Cochlear implants for children and adults with severe to profound deafness
Appraisal Guidance No 165 – Machine perfusion systems and cold static storage of kidneys from deceased donors
Appraisal Guidance No 159 - Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin.
Appraisal Guidance No 160 – Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary pre
Appraisal Guidance No 161
Appraisal Guidance No 158 - Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza
Appraisal Guidance No 156 – Routine antenatal anti-D prophylaxis for women who are rhesus D negative
Appraisal Guidance No 152 – Drug-eluting stents for the treatment of coronary artery disease
Appraisal Guidance No 151 – Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
Appraisal Guidance No 142 – Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia
Appraisal Guidance No 143 – Adalimumab, etanercept and infliximab for ankylosing spondylitis
Appraisal Guidance No 139 – Continuous positive airway pressure for the treatment of obstructive sleep apnoea hypopnoea
Appraisal Guidance 136 - Structural neuroimaging in first-episode psychosis
Appraisal Guidance No 135 - Pemetrexed for the treatment of malignant pleural mesothelioma
Appraisal Guidance No 138 – Inhaled corticosteroids for the treatment of chronic asthma in adults and in children
Nice (Multiple) Technology Appraisal Guidance No: 131 and No: 132
Appraisal Guidance No 130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Appraisal Guidance No 128 Stapled Haemorrhoidopexy for the treatment of haemorrhoids128
Appraisal Guidance No 117 Cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism
Appraisal Gudiance 120 Cardiac resynchronisation (biventricular pacing) therapy for the treatment of heart failure
Appraisal Guidance No 121 Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Appraisal Guidance No 118 Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Appraisal Guidance No 115 Naltrexone for the management of opioid dependence
Appraisal Guidance No 111 Donepezil, galantamine and rivastigmine (review) and memantine for the treatment of Alzheimers
Appraisal Guidance No 104 Etanercept and infliximab for psoriatic arthritis
Appraisal Guidance No 114 Methadone and buprenorphine for the management of opioid dependence
Appraisal Guidance No 105 - Laparoscopic surgery for colorectal cancer
Appraisal Guidance No 102 Children with conduct disorders
Appraisal Guidance No 103 Etanercept and efalizumab for adults with psoriasis
Appraisal Guidance No 101 - Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Appraisal Guidance 100 Oxaliplatin and capecitabine - adjuvant treatment of colorectal cancer
Appraisal Guidance 99 Immunosuppressive therapy - renal transplantation in children
Appraisal Guidance No 98
Appraisal Guidance No 97 Depression and anxiety computerised cognitive behaviour therapy (CCBT)
Appraisal Guidance No 96 - Hepatitis B chronic - adefovir dipivoxil and peginterferon alfa-2a
Appraisal Guidance No 95 - Implantable cardioverter defibrillators for arrhythmias
Appraisal Guidance No 93 - Colorectal cancer advanced- irinotecan, oxaliplatin and raltitrexed
Appraisal Guidance No 92 HealOzone for tooth decay
Appraisal Guidance 91
Appraisal Guidance 90 - Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events
Appraisal Guidance 89 - autologous chondrocyte implantation for the treatment of cartilage defects in knee joints
Appraisal Guidance No 88 - Dual-chamber pacemakers for the treatment of symptomatic bradycardia
Appraisal Guidance No 87 - Prevention of fragility fractures in postmenopausal women
Appraisal Guidance No 83 - Laparoscopic surgery for inguinal hernia repair
Appraisal Guidance No 84 - The use of drotrecogin alfa (activated) for severe sepsis
Appraisal Guidance No 85 - Immunosuppressive therapy for renal transplantation in adults
Appraisal Guidance No 81 - Frequency of application of topical corticosteroids for atopic eczema
Appraisal Guidance No 82 - Tacrolimus and pimecrolimus for atopic eczema
Appraisal Guidance No 80 Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome
Appraisal Guidance No 77 -zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Appraisal Guidance No 78
Appraisal Guidance No. 76 - Newer drugs for epilepsy in adults
Appraisal Guidance No 73 - Myocardial perfusion scintigraphy
Appraisal Guidance No 72 - use of anakinra for rheumatoid arthritis
Appraisal Guidance No 79 - Newer drugs for epilepsy in children
Appraisal Guidance No 74 - pre-hospital initiation of fluid replacement therapy in trauma
Appraisal Guidance No 75 - interferon alfa and ribavirin for the treatment of chronic hepatitis C
Appraisal Guidance No 69 - the use of liquid based cytology for cervical screening
Appraisal Guidance No 70 - Use of imatinib for chronic myeloid leukaemia
Appraisal Guidance No 71 - Use of coronary artery stents
Appraisal Guidance No 68 - Photodynamic therapy for age-related macular degeneration
Appraisal Guidance 65 - the use of rituximab for aggressive non-hodgkin's lymphoma
Appraisal Guidance No 66 - the use of newer drugs for bipolar disorder
Appraisal Guidance 64 - use of somatropin in adults with growth hormone deficiency
Appraisal Guidance No 63 - use of glitazones for the treatment of type 2 diabetes
Appraisal Guidance 61 - use of treatments for colorectal cancer
Appraisal Guidance No 62 - the use of capecitabine for breast cancer
Appraisal Guidance No 54 - The use of vinorelbine for the treatment of advanced breast cancer
Appraisal Guidance 60 - guidance on the use of patient-education models for diabetes
Appraisal Guidance 57 - use of continuous subcutaneous insulin infusion for diabetes
Appraisal Guidance No 56 - use of tension-free vaginal tape for stress incontinence
Appraisal Guidance 58 - use of zanamivir, oseltamivir and amantadine for the treatment of influenza
Appraisal Guidance 59 - Use of electroconvulsive therapy
Appraisal Guidance No 53 - The use of long-acting insulin analogues for the treatment of diabetes - insulin glargine
Appraisal Guidance No 51 - The use of computerised cognitive behaviour therapy for anxiety and depression
Appraisal Guidance No 52 - The use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Appraisal Guidance No 50 - The use of imatinib for chronic myeloid leukaemia
Appraisal Guidance - No. 47 glycoprotein IIb_IIIa inhibitors
Appraisal Guidance - No. 49 ultrasonic locating devices for placing central venous catheter
Appraisal Guidance No. 48 -home compared with hospital haemodialysis for patients with end-stage renal failure
Appraisal Guidance - No. 45 pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian c
Appraisal Guidance - No. 46 surgery to aid weight reduction for people with morbid obesity
Appraisal No108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Appraisal Guidance - No. 44 Guidance on the use of metal-on-metal hip resurfacing arthroplasty
Appraisal Guidance No 43 - Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophreni
Appraisal Guidance - No. 41 Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women
Appraisal Guidance - No. 40 Guidance on the use infliximab for Crohn's disease
Appraisal Guidance - No. 42 Guidance on the use of human growth hormone somatropin in children with growth failure
Appraisal Guidance - No. 34 Guidance on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer
Appraisal Guidance - No. 35 - Etanercept for the treatment of juvenile idiopathic arthritis
Appraisal Guidance - No. 36 Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis
Appraisal Guidance - No. 37 rituximab for recurrent or refractory Stage III or IV follicular non-Hodgkin's lymphoma
Appraisal Guidance - No. 38 Inhaler devices for routine treatment of chronic asthma in older children
Appraisal Guidance - No. 39 Guidance on the use of nicotine replacement therapy (NRT) bupropion for smoking cessation
Appraisal Guidance No. 33: irinotecan, oxaliplatin and raltitrexed for the treatmanet of advanced colorectal cancer
Appraisal Guidance No 32: Beta interferons and glatiramer acetate for the treatment of multiple sclerosis
Appraisal Guidance - No. 31 - The use of sibutramine for the treatment of obesity
Appraisal Guidance No 19 - donepezil, rivastigmine and galantamine for Alzheimer's disease
Appraisal Guidance - No. 30: The use of taxanes for the treatment of breast cancer
Appraisal Guidance - No. 29: The use of fludarabine for B-cell chronic lymphocytic leukaemia
NICE Technology Appraisal Guidance 26
NICE MTA Guidance - No. 28: Topotecan for the treatment of advanced ovarian cancer

Evidence

Latest comments on NICE guidance released

22 May 2013

We released 4 comments:

NICE STA Guidance no 283 - Macular oedema (retinal vein occlusion) - ranibizumab
NICE STA Guidance no 284 -Bevacizumab in combination with paclitaxel and carboplatin for ovarian cancer
NICE STA Guidance no 285 - Bevacizumab in combination with gemcitabine & carboplatin for ovarian cancer
NICE STA guidance 286 - Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal)

NICE Guidance in development

Find the latest news on NICE guidance in development from the NICE website

Our on-going projects

Multiple Technology Appraisals

Contact us

Multiple Technology Appraisals in Scotland

Evidence

Latest comments on NICE guidance released